
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The Castleman Disease Collaborative Network (CDCN) discovered new patient subgroups, based on previously unknown proteomic signatures, with Medidata’s Rave Omics, a machine learning-based solution. These discoveries, presented at the 60th Annual Meeting of the American Society of Hematology, provide insights into treatment response and potential new drug targets, highlighting the value of precision medicine.
Read the full release






